Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Additive Effect of Topical Timolol with 4% Hydroquinone (Kligman's Formula) for Melasma: Face-Split RCT
IRCT20251121068065N1Phase 4Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of timolol, hydroquinone and tretinoin in melasma (2 arms), sponsored by Mashhad University of Medical Sciences. Started May 2026; status: completed.
02
Drugs
timololhydroquinonetretinoin
03
Conditions
melasma
Beyond the preview
Go deeper on IRCT20251121068065N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251121068065N1.